PW
AZN icon

Paladin Wealth’s AstraZeneca AZN Stock Holding History

Paladin Wealth’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
1,657
+189
+13% +$35.5K 0.18% 110
2026
Q1 		$290K Buy
1,468
+263
+22% +$50.7K 0.2% 112
2025
Q4 		$221K Buy
+1,205
New +$211K 0.15% 118
2024
Q4 		– Sell
-66
Closed -$10.2K – 107
2024
Q3 		$10.2K Buy
+66
New +$10.7K 0.01% 178

Other funds holding AZN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
CAM
Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Paladin Wealth's AZN Position: Q2 2026 in Review

Paladin Wealth increased its AstraZeneca (AZN) stake by 13% in Q2 2026, buying an estimated $35.5K and bringing the position to 1,657 shares worth $314K. The position accounts for 0.18% of the portfolio, ranked #110.

Paladin Wealth first reported a position in AZN in Q3 2024 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Paladin Wealth held 1,657 shares of AstraZeneca worth $314K as of Q2 2026.
  • Paladin Wealth bought 189 AstraZeneca shares in Q2 2026, an estimated $35.5K.
  • AstraZeneca made up 0.18% of Paladin Wealth's portfolio in Q2 2026, its #110 holding.
  • Paladin Wealth first reported a position in AstraZeneca in Q3 2024 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Paladin Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.